Evidence Table 22Study characteristics for studies on the effect of testing on management


Reference List
  1. Vossen CY, Walker ID, Svensson P et al. Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. Arterioscler Thromb Vasc Biol 2005; 25(9):1992–7.
  2. Wahlander K, Eriksson H, Lundstrom T et al. Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism. Br J Haematol 2006; 133(1):68–77.
    Notes: CORPORATE NAME: THRIVE III Investigators
  3. Kearon C, Julian JA, Kovacs MJ et al. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: Results from a randomized trial. Blood 2008.
  4. Ridker PM, Goldhaber SZ, Danielson E et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348(15):1425–34.
    Notes: CORPORATE NAME: PREVENT Investigators

From: Appendix G, Evidence Tables

Cover of Outcomes of Genetic Testing in Adults with a History of Venous Thromboembolism
Outcomes of Genetic Testing in Adults with a History of Venous Thromboembolism.
Evidence Reports/Technology Assessments, No. 180.
Segal JB, Brotman DJ, Emadi A, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.